Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
Do you use altered fractionation in patients with locally advanced head and neck cancers who are not candidates for chemotherapy?
Answer from: Radiation Oncologist at Academic Institution
yes
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Academic Institution
yes
Sign In
or
Register
to read more
397
400
Related Questions
How would you approach a patient treated for a stage I glottic cancer 2 years prior with a biopsy proven recurrence who is declining surgery and any systemic therapy?
What is the role for chemo immunotherapy in the up front setting in non-metastatic head & neck cancer outside of clinical trials?
How do you approach cisplatin dosing for locally advanced head and neck SCC in HPV-positive and HPV-negative patients?
For a patient with a salivary gland tumor with evidence of local recurrence would you recommend 6 weekly fractions if giving RT alone?
How do you counsel patients regarding alcohol consumption following treatment of head and neck cancer?
What's the role of contralateral neck re-irradiation in the post-op setting for someone with a remote history of head and neck cancer who underwent definitive RT with elective dose to the bilateral neck now with a new primary s/p surgery with ipsilateral neck dissection requiring post op chemo radiation for bony involvement and ENE?
How would you approach post-op radiation recommendations in patients who had neoadjuvant chemoimmunotherapy for HPV mediated OPSCC s/p TORS who have a complete pathologic response (pCR)?
How are you integrating the findings from KEYNOTE-689 into daily practice?
What is the preferred neoadjuvant/adjuvant chemotherapy regimen for HPV-associated nasopharyngeal cancer?
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
